Published in Oncotarget on October 13, 2015
Low-dose methotrexate enhances cycling of highly anaplastic cancer cells. Cell Cycle (2016) 0.84
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
On respiratory impairment in cancer cells. Science (1956) 14.07
Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature (2009) 9.75
Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev (2005) 7.27
Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 7.10
Epigenetic reprogramming and induced pluripotency. Development (2009) 4.90
Induced pluripotency: history, mechanisms, and applications. Genes Dev (2010) 4.89
Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab (2011) 4.15
Nuclear reprogramming and pluripotency. Nature (2006) 3.68
Chromatin connections to pluripotency and cellular reprogramming. Cell (2011) 3.07
The role of hypoxia in the maintenance of hematopoietic stem cells. Blood (1993) 2.59
Nuclear transplantation, embryonic stem cells, and the potential for cell therapy. N Engl J Med (2003) 2.50
Hypoxia inducible factors in cancer stem cells. Br J Cancer (2010) 2.21
Hypoxia or in situ normoxia: The stem cell paradigm. J Cell Physiol (2009) 2.14
Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A (2009) 2.11
Embryonic transcription factors in human breast cancer. IUBMB Life (2006) 1.95
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res (1991) 1.94
Genome-wide chromatin interactions of the Nanog locus in pluripotency, differentiation, and reprogramming. Cell Stem Cell (2013) 1.91
Chromatin dynamics during cellular reprogramming. Nature (2013) 1.79
Tetrahydrofolate and tetrahydromethanopterin compared: functionally distinct carriers in C1 metabolism. Biochem J (2000) 1.48
Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations. Leukemia (2006) 1.14
The expanding role of miR-302-367 in pluripotency and reprogramming. Cell Cycle (2012) 1.13
DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation. Proc Natl Acad Sci U S A (2008) 1.10
The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy. Cell Cycle (2014) 1.09
Cancer research: from folate antagonism to molecular targets. Best Pract Res Clin Haematol (2009) 1.08
Properties of the K562 cell line derived from a patient with chronic myeloid leukemia. Int J Cancer (1977) 1.04
The reprogramming language of pluripotency. Curr Opin Genet Dev (2008) 1.02
Environmental restrictions within tumor ecosystems select for a convergent, hypoxia-resistant phenotype of cancer stem cells. Cell Cycle (2007) 1.01
Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate. Haematologica (2010) 0.95
A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res (1994) 0.95
Hypoxia-resistant profile implies vulnerability of cancer stem cells to physiological agents, which suggests new therapeutic targets. Cell Cycle (2013) 0.94
Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Invest New Drugs (1996) 0.94
Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia. PLoS One (2011) 0.93
Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clin Cancer Res (2000) 0.92
The involvement of a Nanog, Klf4 and c-Myc transcriptional circuitry in the intertwining between neoplastic progression and reprogramming. Cell Cycle (2012) 0.91
Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer (1998) 0.90
Cellular reprogramming and hepatocellular carcinoma development. World J Gastroenterol (2013) 0.86
The respiration-linked limiting step of tumor cell transition from the non-cycling to the cycling state: its inhibition by oxidizable substrates and its relationships to purine metabolism. J Cell Physiol (1983) 0.85
Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Blood (1997) 0.85
Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res (2005) 0.81
Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Clin Cancer Res (1998) 0.80
Rearranging the chromatin for pluripotency. Cell Cycle (2013) 0.77
Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug. J Cancer Res Clin Oncol (1996) 0.76
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol (2014) 1.79
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. Oncol Res (2017) 0.75